AMP Starts Position in Anthera Pharmaceuticals


Today AMP started a position in Anthera Pharmaceuticals (ANTH) by purchasing 14,792 shares at $1.69/share in a transaction totaling ~$25K.

Anthera Pharmaceuticals is a clinical stage company developing two clinical assets: Sollpura the first non-pig derived pancreatic enzyme replacement therapy (PERT) for patients with cystic fibrosis and endocrine pancreatic insufficiency and Blisibimod for treatment of IgA nephropathy (IgAN).


0 comments